Israel Englander’s Tarsus Pharmaceuticals TARS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$89.8M Buy
1,427,124
+862,545
+153% +$55.1M 0.03% 556
2026
Q1
$39.6M Buy
564,579
+447,575
+383% +$31.3M 0.02% 1006
2025
Q4
$9.58M Buy
117,004
+16,436
+16% +$1.23M ﹤0.01% 2313
2025
Q3
$5.98M Buy
100,568
+42,427
+73% +$2.09M ﹤0.01% 2952
2025
Q2
$2.36M Sell
58,141
-189,054
-76% -$8.51M ﹤0.01% 3734
2025
Q1
$12.7M Sell
247,195
-396,815
-62% -$19.6M 0.01% 1942
2024
Q4
$35.7M Buy
644,010
+421,495
+189% +$19.1M 0.02% 1029
2024
Q3
$7.32M Sell
222,515
-126,071
-36% -$3.54M ﹤0.01% 2494
2024
Q2
$9.47M Buy
348,586
+322,942
+1,259% +$10.9M ﹤0.01% 2123
2024
Q1
$932K Sell
25,644
-172,810
-87% -$5.08M ﹤0.01% 4348
2023
Q4
$4.02M Sell
198,454
-609,707
-75% -$10.2M ﹤0.01% 2969
2023
Q3
$14.4M Buy
808,161
+737,489
+1,044% +$13.1M 0.01% 1708
2023
Q2
$1.28M Buy
70,672
+57,285
+428% +$911K ﹤0.01% 3840
2023
Q1
$168K Buy
+13,387
New +$196K ﹤0.01% 5244
2021
Q2
Sell
-84,854
Closed -$2.73M 7094
2021
Q1
$2.73M Sell
84,854
-59,382
-41% -$2.2M ﹤0.01% 3225
2020
Q4
$5.96M Buy
+144,236
New +$4.11M ﹤0.01% 2271

Other funds holding TARS

Israel Englander's TARS Position: Q2 2026 in Review

Israel Englander increased its Tarsus Pharmaceuticals (TARS) stake by 153% in Q2 2026, buying an estimated $55.1M and bringing the position to 1,427,124 shares worth $89.8M. The position accounts for 0.03% of the portfolio, ranked #556.

Israel Englander first reported a position in TARS in Q4 2020 and has held it in 16 quarters since. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Israel Englander held 1,427,124 shares of Tarsus Pharmaceuticals worth $89.8M as of Q2 2026.
  • Israel Englander bought 862,545 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $55.1M.
  • Tarsus Pharmaceuticals made up 0.03% of Israel Englander's portfolio in Q2 2026, its #556 holding.
  • Israel Englander first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.